Literature DB >> 26421877

Role of Species-Specific Primary Structure Differences in Aβ42 Assembly and Neurotoxicity.

Robin Roychaudhuri1, Xueyun Zheng2, Aleksey Lomakin3, Panchanan Maiti1, Margaret M Condron1, George B Benedek3, Gal Bitan1,4, Michael T Bowers2, David B Teplow1,4.   

Abstract

A variety of species express the amyloid β-protein (Aβ (the term "Aβ" refers both to Aβ40 and Aβ42, whereas "Aβ40" and "Aβ42" refer to each isoform specifically). Those species expressing Aβ with primary structure identical to that expressed in humans have been found to develop amyloid deposits and Alzheimer's disease-like neuropathology. In contrast, the Aβ sequence in mice and rats contains three amino acid substitutions, Arg5Gly, His13Arg, and Tyr10Phe, which apparently prevent the development of AD-like neuropathology. Interestingly, the brush-tailed rat, Octodon degus, expresses Aβ containing only one of these substitutions, His13Arg, and does develop AD-like pathology. We investigate here the biophysical and biological properties of Aβ peptides from humans, mice (Mus musculus), and rats (Octodon degus). We find that each peptide displays statistical coil → β-sheet secondary structure transitions, transitory formation of hydrophobic surfaces, oligomerization, formation of annuli, protofibrils, and fibrils, and an inverse correlation between rate of aggregation and aggregate size (faster aggregation produced smaller aggregates). The rank order of assembly rate was mouse > rat > Aβ42. The rank order of neurotoxicity of assemblies formed by each peptide immediately after preparation was Aβ42 > mouserat. These data do not support long-standing hypotheses that the primary factor controlling development of AD-like neuropathology in rodents is Aβ sequence. Instead, the data support a hypothesis that assembly quaternary structure and organismal responses to toxic peptide assemblies mediate neuropathogenetic effects. The implication of this hypothesis is that a valid understanding of disease causation within a given system (organism, tissue, etc.) requires the coevaluation of both biophysical and cell biological properties of that system.

Entities:  

Keywords:  Alzheimer's disease; Amyloid β-protein; aggregation; humans; mice; neurotoxicity; rats

Mesh:

Substances:

Year:  2015        PMID: 26421877      PMCID: PMC4844016          DOI: 10.1021/acschemneuro.5b00180

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  66 in total

Review 1.  Changes in cognition.

Authors:  Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  SnapShot: pathobiology of Alzheimer's disease.

Authors:  Dennis J Selkoe
Journal:  Cell       Date:  2013-07-18       Impact factor: 41.582

3.  Dimer formation from 1-amino-8-naphthalenesulfonate catalyzed by bovine serum albumin. A new fluorescent molecule with exceptional binding properties.

Authors:  C G Rosen; G Weber
Journal:  Biochemistry       Date:  1969-10       Impact factor: 3.162

4.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease.

Authors:  Summer L Bernstein; Nicholas F Dupuis; Noel D Lazo; Thomas Wyttenbach; Margaret M Condron; Gal Bitan; David B Teplow; Joan-Emma Shea; Brandon T Ruotolo; Carol V Robinson; Michael T Bowers
Journal:  Nat Chem       Date:  2009-07       Impact factor: 24.427

Review 5.  The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins.

Authors:  D J Selkoe
Journal:  Neurol Clin       Date:  2000-11       Impact factor: 3.806

6.  Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe.

Authors:  G V Semisotnov; N A Rodionova; O I Razgulyaev; V N Uversky; A F Gripas'; R I Gilmanshin
Journal:  Biopolymers       Date:  1991-01       Impact factor: 2.505

7.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

8.  Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu.

Authors:  Nibaldo C Inestrosa; Ariel E Reyes; Marcelo A Chacón; Waldo Cerpa; Aldo Villalón; Juan Montiel; Genevieve Merabachvili; Rebeca Aldunate; Francisco Bozinovic; Francisco Aboitiz
Journal:  Neurobiol Aging       Date:  2004-12-10       Impact factor: 4.673

9.  Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides.

Authors:  Farid Rahimi; Panchanan Maiti; Gal Bitan
Journal:  J Vis Exp       Date:  2009-01-12       Impact factor: 1.355

10.  A generic mechanism of emergence of amyloid protofilaments from disordered oligomeric aggregates.

Authors:  Stefan Auer; Filip Meersman; Christopher M Dobson; Michele Vendruscolo
Journal:  PLoS Comput Biol       Date:  2008-11-14       Impact factor: 4.475

View more
  11 in total

1.  Relevance of transgenic mouse models for Alzheimer's disease.

Authors:  Leon M Tai; Juan Maldonado Weng; Mary Jo LaDu; Scott T Brady
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-24       Impact factor: 3.622

2.  Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.

Authors:  Tina Bilousova; Mikhail Melnik; Emily Miyoshi; Bianca L Gonzalez; Wayne W Poon; Harry V Vinters; Carol A Miller; Maria M Corrada; Claudia Kawas; Asa Hatami; Ricardo Albay; Charles Glabe; Karen H Gylys
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

Review 3.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

4.  1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose Binds to the N-terminal Metal Binding Region to Inhibit Amyloid β-protein Oligomer and Fibril Formation.

Authors:  Natália E C de Almeida; Thanh D Do; Nichole E LaPointe; Michael Tro; Stuart C Feinstein; Joan-Emma Shea; Michael T Bowers
Journal:  Int J Mass Spectrom       Date:  2016-09-30       Impact factor: 1.986

Review 5.  The role of APOE in transgenic mouse models of AD.

Authors:  Deebika Balu; Aimee James Karstens; Efstathia Loukenas; Juan Maldonado Weng; Jason M York; Ana Carolina Valencia-Olvera; Mary Jo LaDu
Journal:  Neurosci Lett       Date:  2019-05-28       Impact factor: 3.046

6.  Solid Lipid Curcumin Particles Induce More DNA Fragmentation and Cell Death in Cultured Human Glioblastoma Cells than Does Natural Curcumin.

Authors:  Panchanan Maiti; Abeer Al-Gharaibeh; Nivya Kolli; Gary L Dunbar
Journal:  Oxid Med Cell Longev       Date:  2017-11-19       Impact factor: 6.543

7.  Amyloid β peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice.

Authors:  Tuhina Prasad; Ping Zhu; Amrisha Verma; Paramita Chakrabarty; Awilda M Rosario; Todd E Golde; Qiuhong Li
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

8.  Alzheimer Aβ Assemblies Accumulate in Excitatory Neurons upon Proteasome Inhibition and Kill Nearby NAKα3 Neurons by Secretion.

Authors:  Hitomi Komura; Shota Kakio; Tomoya Sasahara; Yoshie Arai; Naomi Takino; Michio Sato; Kaori Satomura; Takayuki Ohnishi; Yo-Ichi Nabeshima; Shin-Ichi Muramatsu; Isao Kii; Minako Hoshi
Journal:  iScience       Date:  2019-02-28

9.  Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments.

Authors:  Panchanan Maiti; Alexandra Plemmons; Gary L Dunbar
Journal:  PLoS One       Date:  2019-12-16       Impact factor: 3.240

10.  Comparative Neuroprotective Effects of Dietary Curcumin and Solid Lipid Curcumin Particles in Cultured Mouse Neuroblastoma Cells after Exposure to Aβ42.

Authors:  Panchanan Maiti; Gary L Dunbar
Journal:  Int J Alzheimers Dis       Date:  2017-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.